Mon, Jul 28, 2014, 3:20 PM EDT - U.S. Markets close in 40 mins.

Recent

% | $
Click the to save as a favorite.

Alnylam Pharmaceuticals, Inc. Message Board

robert.vince 22 posts  |  Last Activity: Jul 21, 2014 7:49 AM Member since: Aug 30, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Getting the word out:

    Stellar Biotechnolgies announced today it has retained Stonegate, Inc. ("Stonegate") to provide institutional investor outreach and capital markets advisory for the Company pending regulatory approval.

    "Stellar has reached a key point of our business development and immunotherapy research program where we believe we are well positioned to increase our institutional outreach efforts. Our core business of manufacture and supply of KLH protein continues to strengthen our position to negotiate alliances with commercial partners in parallel with their clinical successes. We continue to make breakthroughs in aquaculture science and our immunotherapy program targeting Clostridium difficile ("C. diff") is on track to deliver data midsummer. These achievements coupled with our strong financial position to support our efforts, reinforces my confidence that we have a compelling story to tell," said Frank Oakes, president and chief executive officer of Stellar Biotechnologies. "Stonegate's team has more than a 40-year track record of success connecting growth companies with institutional investors. Their highly focused approach to deliver effective and innovative targeting solutions should help expand our institutional awareness and shareholder base."

    Stonegate is a 40-year old research, capital markets advisory and investment banking boutique dedicated to serving the specialized needs of small-cap public companies. Stonegate provides research, sales and trading, corporate finance, strategic advisory and investor relations' services to a select group of clients. They work with the leading institutional investors in the U.S. and Europe who are seeking high quality investment opportunities in the small cap marketplace.

    Stonegate will receive a fee of US $5,000 per month for six months through September 30, 2014, with an optional monthly renewal thereafter. The agreement may be cancelled after the initial six-month term upon 10 days written notice.

  • Melbourne, Australia; Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2014.

    The cash balance at 31 March 2014 was $27.8 million. This strong cash position was assisted by the receipt of $4.7 million of R&D tax incentive relating to FY13 expenditures.

    The March quarter saw a high level of activity for the Company. The DEPTM docetaxel Phase 1 trial commenced in January, with the first patient cohort now enrolled and commenced treatment. Multiple clinical trial preparations have also occurred for the Phase 3 VivaGel® bacterial vaginosis (BV) prevention program during the quarter. Expenditure for the quarter included the manufacture of clinical trial product for both the DEPTM docetaxel and VivaGel® clinical trials.

    Preparation for Phase 3 clinical trials for VivaGel® to prevent recurrent BV are now well advanced. During the period, activities undertaken in preparation for the commencement of this multi-site trial program include site selection, briefing of clinical investigators, site preparation, ethics submissions, and clinical product manufacturing. The company expects to commence the trials shortly.

    Starpharma has made significant advances related to its VivaGel® BV symptomatic relief product, including discussions with several key regulatory bodies. The Company is now preparing for regulatory submissions in key markets in coming months, in parallel with ongoing positive discussions with commercial partners.

    In March, Starpharma announced that its commercial partner in Japan, Okamoto Industries, received regulatory approval for the VivaGel®-coated condom in that country, and the Company is working with Okamoto in preparation for product launch.

    In addition, Starpharma continues to work closely with Ansell Limited towards regulatory approval and subsequent launch of the VivaGel®-coated condom in a number of markets. Ansell has rights to the VivaGel®-coated condom in countries outside Japan.

    In early April, Starpharma announced an expanded agreement with AstraZeneca in the field of cancer medicine using Starpharma’s proprietary DEP™ dendrimer drug delivery technology.

    Starpharma Chief Executive, Dr Jackie Fairley, said: “The first quarter of 2014 has been a very active period for Starpharma as we advance a number of clinical trial and regulatory processes related to the VivaGel® suite of products and our drug delivery programs. It has also been a period of significant commercial advancement with the VivaGel®-coated condom now approved for launch in Japan, licensing discussions for BV continuing positively, and our agreement with AstraZeneca extended to develop dendrimer enhanced cancer products.”

ALNY
53.56-1.27(-2.32%)3:19 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.